Emmerson PLC (AIM:EML, OTC:EMSNF) is well positioned to take advantage of the fertiliser market, said analysts at Shore Capital and Liberum.
Shore Capital said the potash development company is “fully funded to complete the detailed engineering work and remaining permitting and project financing processes through to a construction decision.”
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) accompanied full year results with fund-raising plans as it gears up for the start of two key clinical trials in its innovative immunotherapy pipeline.
The specialty pharmaceutical company announced a subscription by Southern Fox and ZQ Capital to raise £7mln at an issue price of 20p per share and the issue of loan notes to raise a further £10mln.
Kodal Minerals PLC (AIM:KOD) is in talks to finance its Bougouni lithium project in Mali based on a capital cost of accelerating the development through a dense media separation (DMS) processing plant option estimated to be US$65mln, with a payback of two months once operations start if fully funded by equity.
With this capital development cost covering all associated infrastructure and commencement of mining, the company estimated this would generate an estimated NPV7% of approximately US$557mln, or US$420mln post-tax, with revenue forecast to exceed US$1.05bn in less than four years, based a price averaging US$2,080 per tonne of lithium, well below the recent spot prices above US$5,000.
Bango PLC (AIM:BGO, OTCQX:BGOPF) said it is well positioned to take market share as the mobile payments specialist delivered a solid set of interim results.
“The pipeline for the second half of 2022 and beyond is strong,” investors were told.
Researchers working with ANGLE PLC (AIM:AGL, OTCQX:ANPCY)’s Parsortix liquid biopsy system have been able to successfully tell the difference between malignant and benign abnormal pelvic masses using a simple blood draw to help detect ovarian cancer.
The company called the results ‘best in class’ and pointed out the approach has the potential to at least cut in half the number of false positive and negative results current screening methods throw up.
Metal Tiger Plc (AIM:MTR, OTC:MRTTF, ASX:MTR) told investors it has opted to extend its margin lending facility for an additional 12 months, until October 2023, for a fee of A$83,035. The company, meanwhile, settled outstanding interest payments amounting to A$250,566, and, the facility has an outstanding balance of A$4.68mln.
Ethernity Networks Ltd (AIM:ENET, OTCQB:ENETF) announced it had received a settlement notice for US$320,000 from 5G Innovation Leaders Fund LLC, under a share subscription agreement from February 2022, and, the facility has a balance of US$1.74mln.
Quantum Blockchain Technologies Plc's (AIM:QBT) sale & repurchase agreement (REPO) entered into between the chief executive officer Professor Francesco Gardin and MC Strategies AG has been amended with a new repurchase price and repurchase date.
The repurchase price for the 5mln ordinary shares to be bought by Professor Gardin has been amended to 3.15p per share, extended to December 16, 2022. All other terms of the REPO remained unchanged.
Open Orphan Plc (AIM:ORPH, OTC:OPORF) chief executive Yamin 'Mo' Khan bought 510,204 shares in the company, priced at 9.8p, representing 0.08% of the company. In statement, he said: "The purchase of shares in the company demonstrates both my commitment and my confidence in our long-term growth strategy. Since my appointment as CEO in February 2022, we have made significant progress, delivering continued growth and a record orderbook valued at c.£80m as of 1 September, which provides excellent forward visibility into H2 2022 and 2023."
Chamberlin Plc (AIM:CMH) told investors it has been informed by its auditors that the audit for the year ended 31 May 2022 is taking longer than anticipated. It added that it expects the audited results to be in line with the results included in the Company's trading update dated 8 July 2022. It is aiming to report final results by the end of October 2022.